Open Access

Clinical study of Shengxuening tablet combined with rHuEPO for the treatment of renal anemia of maintenance hemodialysis patients

  • Authors:
    • Xin Cheng
    • Guojun Yu
    • Jiangping Hu
    • Xuefeng Xu
    • Fang Luo
    • Ping Shen
    • Guosheng Zhang
    • Ning Yang
  • View Affiliations

  • Published online on: April 28, 2016     https://doi.org/10.3892/etm.2016.3307
  • Pages: 157-160
  • Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the clinical effects of Shengxuening tablet (silkworm excrement) combined with recombinant human erythropoietin (rHuEPO) for the treatment of renal anemia of maintenance hemo­dialysis (MHD) patients. Seventy-two MHD patients with renal anemia were included in the study and randomly divided into the control (n=34) and observation (n=38) groups. Patients in the control group were treated by hypodermic injection of 100-150 U/(kg·w) rHuEPO and patients in the observation group were treated by rHuEPO + 1.0 g t.i.d. p.o. Shengxuening tablet. The two groups were assisted by conventional treatments including iron, folic acid, vitamin B12 and L-carnitine. After 3 and 6 months, improvement of anemia was compared. After 3 months, the hemoglobin, hematocrit, serum ferritin and transferrin saturation levels of the observation group were significantly higher than those of the control group (p<0.05). In addition, C-reactive protein and superoxide dismutase levels of the observation group were significantly lower than those of the control group (p<0.05). After 6 months, indices of the observation group were ameliorated while the improvement of control group was not obvious, and indices of the observation group were significantly higher than those of the control group (p<0.05). Consumption of rHuEPO in the observation group was significantly less than that of the control group, and the total effective rate was significantly higher than that of the control group (p<0.05). In conclusion, Shengxuening tablet combined with rHuEPO was safe and effective for the treatment of renal anemia of MHD patients.
View References

Related Articles

Journal Cover

July-2016
Volume 12 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cheng X, Yu G, Hu J, Xu X, Luo F, Shen P, Zhang G and Yang N: Clinical study of Shengxuening tablet combined with rHuEPO for the treatment of renal anemia of maintenance hemodialysis patients. Exp Ther Med 12: 157-160, 2016.
APA
Cheng, X., Yu, G., Hu, J., Xu, X., Luo, F., Shen, P. ... Yang, N. (2016). Clinical study of Shengxuening tablet combined with rHuEPO for the treatment of renal anemia of maintenance hemodialysis patients. Experimental and Therapeutic Medicine, 12, 157-160. https://doi.org/10.3892/etm.2016.3307
MLA
Cheng, X., Yu, G., Hu, J., Xu, X., Luo, F., Shen, P., Zhang, G., Yang, N."Clinical study of Shengxuening tablet combined with rHuEPO for the treatment of renal anemia of maintenance hemodialysis patients". Experimental and Therapeutic Medicine 12.1 (2016): 157-160.
Chicago
Cheng, X., Yu, G., Hu, J., Xu, X., Luo, F., Shen, P., Zhang, G., Yang, N."Clinical study of Shengxuening tablet combined with rHuEPO for the treatment of renal anemia of maintenance hemodialysis patients". Experimental and Therapeutic Medicine 12, no. 1 (2016): 157-160. https://doi.org/10.3892/etm.2016.3307